{{Drugbox
| IUPAC_name = ''N''-[(2''S'')-1-amino-1-oxo-3-phenylpropan-2-yl]-1-(cyclohexylmethyl)indazole-3-carboxamide
| image = APP-CHMINACA.svg

<!--Clinical data-->
| tradename =  
| pregnancy_AU = 
| pregnancy_US = 
| pregnancy_category =  
| legal_AU = 
| legal_CA = Schedule II
| legal_UK = 
| legal_US = 
| legal_status = Illegal in Sweden
| routes_of_administration =  

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =  

<!--Identifiers-->
| CAS_number_Ref = 
| CAS_number = 1185887-14-2
| ATC_prefix =  
| ATC_suffix =  
| PubChem = 44206137
| ChemSpiderID      = 48063640
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 3877T06H05
| smiles            = NC(=O)[C@H](Cc1ccccc1)NC(=O)c2nn(CC3CCCCC3)c4ccccc24
| StdInChI          = 1S/C24H28N4O2/c25-23(29)20(15-17-9-3-1-4-10-17)26-24(30)22-19-13-7-8-14-21(19)28(27-22)16-18-11-5-2-6-12-18/h1,3-4,7-10,13-14,18,20H,2,5-6,11-12,15-16H2,(H2,25,29)(H,26,30)/t20-/m0/s1
| StdInChIKey       = DMHWDSGURMXMGE-FQEVSTJZSA-N

<!--Chemical data-->
| C=24 | H=28 | N=4 | O=2 
| molecular_weight = 404.5 g/mol
}}

'''PX-3''' (also known as '''APP-CHMINACA''') is an [[indazole]]-based [[synthetic cannabinoid]]. It is a potent [[agonist]] of the [[CB1 receptor|CB<sub>1</sub> receptor]] with a binding affinity of ''K''<sub>i</sub>&nbsp;=&nbsp;47.6&nbsp;nM and was originally developed by [[Pfizer]] in 2009 as an [[analgesic]] medication.<ref>{{cite web | url=https://www.caymanchem.com/app/template/Product.vm/catalog/17614 | title=APP-CHMINACA | publisher=Cayman Chemical | accessdate=24 June 2015}}</ref><ref>{{cite journal | url=https://www.google.com/patents/WO2009106980A3 | title=Patent WO/2009/106980 - Indazole derivatives}}</ref><ref>{{cite web | url=https://forum.goeg.at/EwsForum/default.aspx?g=posts&t=211 | title=EWS Forum - In Belgien wurde die neue psychoaktive Substanz N-(2-amino-1-benzyl-2-oxo-ethyl)-1-(cyclohexylmethyl)indazole-3-carboxamide (APP-CHMINACA) identifiziert. | accessdate=24 June 2015}}</ref>

The acronym 'APP' signifies the 'amino', 'phenyl' and 'propanone' elements of the structure. Three related compounds, [[PX-1]] (5F-APP-PICA, SRF-30), [[PX-2]] (5F-APP-PINACA, FU-PX) and [[APP-FUBINACA]] were reported by the [[European Monitoring Centre for Drugs and Drug Addiction|EMCDDA]] in late 2014.<ref>{{cite web | url=https://forum.goeg.at/EwsForum/default.aspx?g=posts&t=194 | title=EWS Forum - In Schweden wurde die neue psychoaktive Substanz ''N''-(1-amino-1-oxo-3-phenylpropan-2-yl)-1-(5-fluoropentyl)-1''H''-indole-3-carboxamide (5F-APP-PICA) identifiziert. | accessdate=24 June 2015}}</ref><ref>{{cite web | url=https://forum.goeg.at/EwsForum/default.aspx?g=posts&t=193 | title=EWS Forum - In Schweden wurden folgende drei neue psychoaktive Substanzen identifiziert. | accessdate=24 June 2015}}</ref>

==Legality==
Sweden's public health agency suggested to classify APP-CHMINACA as hazardous substance on June 1, 2015.<ref>{{cite web | url=http://www.folkhalsomyndigheten.se/nyheter-och-press/nyhetsarkiv/2015/juni/23-nya-amnen-kan-klassas-som-narkotika-eller-halsofarlig-vara | title=23 nya ämnen kan klassas som narkotika eller hälsofarlig vara | publisher=Folkhälsomyndigheten | accessdate=29 June 2015}}</ref>

==See also==
{{div col|colwidth=30em}}
* [[5F-AB-PINACA]]
* [[5F-ADB]]
* [[5F-AMB]]
* [[5F-APINACA]]
* [[AB-FUBINACA]]
* [[AB-CHFUPYCA]]
* [[AB-CHMINACA]]
* [[AB-PINACA]]
* [[ADB-CHMINACA]]
* [[ADB-FUBINACA]]
* [[ADB-PINACA]]
* [[ADBICA]]
* [[APICA]]
* [[APINACA]]
* [[MDMB-CHMICA]]
* [[PX-1]]
* [[PX-2]]
{{Div col end}}

==References==
{{Reflist}}

{{Cannabinoids}}
{{Cannabinoidergics}}

[[Category:Indazoles]]
[[Category:Cannabinoids]]
[[Category:Designer drugs]]
[[Category:Indazolecarboxamides]]

{{cannabinoid-stub}}